Submissions from 2018
Correction to: Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial., J A Walsh, A B Gottlieb, B Hoepken, T Nurminen, and P J Mease
Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial., J A Walsh, A B Gottlieb, B Hoepken, T Nurminen, and P J Mease
Percutaneous Ultrasonic Tenotomy for Refractory Common Extensor Tendinopathy After Failed Open Surgical Release: A Report of Two Cases., Reed C Williams and Adam M Pourcho
The unmet need in rheumatology: Reports from the targeted therapies meeting 2017., Kevin L Winthrop, Vibeke Strand, Désirée van der Heijde, Philip Mease, Mary Crow, Michael Weinblatt, Joan Bathon, Gerd R Burmester, Maxime Dougados, Johnathan Kay, Xavier Mariette, Ronald Van Vollenhoven, Joachim Sieper, Fritz Melchers, Ferdinand C Breedfeld, Joachim Kalden, Josef S Smolen, and Daniel E Furst
Submissions from 2017
The feasibility of implementing the ICHOM Standard Set for Hip and Knee Osteoarthritis: a mixed-methods evaluation in public and private hospital settings., Ilana N Ackerman, Bernarda Cavka, Jacob Lippa, and Andrew Bucknill
International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting., Laura C Coates, Vinod Chandran, Alexis Ogdie, Denis O'Sullivan, Mel Brooke, Ingrid Steinkoenig, Philip Mease, Christopher T Ritchlin, and Arthur Kavanaugh
Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1., Laura C Coates, Mitsumasa Kishimoto, Alice Gottlieb, Catherine L Shuler, Chen-Yen Lin, Chin Hyok Lee, and Philip Mease
GRAPPA 2016 Project Report., Philip S Helliwell, Oliver FitzGerald, Laura C Coates, Kristina Callis Duffin, and Philip Mease
Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis., D H Huynh, T A Boyd, C J Etzel, V Cox, J Kremer, P Mease, and A Kavanaugh
Proceedings of the GRAPPA 2016 Retreat., Deepak R Jadon, Dafna D Gladman, Philip Mease, Oliver FitzGerald, Vinod Chandran, Niti Goel, Cheryl F Rosen, Walter P Maksymowych, Christopher T Ritchlin, Alexis Ogdie, Laura C Coates, Alberto Cauli, Enrique R Soriano, M Elaine Husni, Willemina Campbell, Valderilio F Azevedo, Kristina Callis Duffin, April W Armstrong, Alice B Gottlieb, Arthur Kavanaugh, Amit Garg, and Philip S Helliwell
Societal costs and patients' experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study., Lars Erik Kristensen, Tanja S Jørgensen, Robin Christensen, Henrik Gudbergsen, Lene Dreyer, Christine Ballegaard, Lennart T H Jacobsson, Vibeke Strand, Philip Mease, and Jakob Kjellberg
Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study., Iain B McInnes, Philip Mease, Christopher T Ritchlin, Proton Rahman, Alice B Gottlieb, Bruce Kirkham, Radhika Kajekar, Eumorphia-Maria Delicha, Luminita Pricop, and Shephard Mpofu
New pathways of treatment for psoriatic arthritis., Philip Mease
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis., Philip Mease, Alice B Gottlieb, Désirée van der Heijde, Oliver FitzGerald, Alyssa Johnsen, Marleen Nys, Subhashis Banerjee, and Dafna D Gladman
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis., Philip Mease, Stephen Hall, Oliver FitzGerald, Désirée van der Heijde, Joseph F Merola, Francisco Avila-Zapata, Dorota Cieślak, Daniela Graham, Cunshan Wang, Sujatha Menon, Thijs Hendrikx, and Keith S Kanik
Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry., Philip Mease, Chitra Karki, Jacqueline B Palmer, Carol J Etzel, Arthur Kavanaugh, Christopher T Ritchlin, Wendi Malley, Vivian Herrera, Melody Tran, and Jeffrey D Greenberg
Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial., Philip Mease, Arthur Kavanaugh, Laura C Coates, Iain B McInnes, Maja Hojnik, Ying Zhang, Jaclyn K Anderson, Alexander P Dorr, and Dafna D Gladman
Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry., Philip Mease, Tamara Lesperance, Mei Liu, David H Collier, Marc Mason, Sabrina Deveikis, and Neil A Accortt
Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab., Philip Mease, Filip Van den Bosch, Joachim Sieper, Yinglin Xia, Aileen L Pangan, and In-Ho Song
Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group., Alexis Ogdie, Maarten de Wit, Kristina Callis Duffin, Willemina Campbell, Jeffrey Chau, Laura C Coates, Lihi Eder, Musaab Elmamoun, Oliver FitzGerald, Dafna D Gladman, Niti Goel, Jana James, Umut Kalyoncu, John Latella, Chris Lindsay, Philip Mease, Denis O'Sullivan, Ingrid Steinkoenig, Vibeke Strand, William Tillett, and Ana-Maria Orbai
Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016., Ana-Maria Orbai, Maarten de Wit, Philip Mease, Kristina Callis Duffin, Musaab Elmamoun, William Tillett, Willemina Campbell, Oliver FitzGerald, Dafna D Gladman, Niti Goel, Laure Gossec, Pil Hoejgaard, Ying Ying Leung, Chris Lindsay, Vibeke Strand, Désirée M van der Heijde, Bev Shea, Robin Christensen, Laura Coates, Lihi Eder, Neil McHugh, Umut Kalyoncu, Ingrid Steinkoenig, and Alexis Ogdie
Total Ankle Replacement with Severe Valgus Deformity: Technique and Surgical Strategy., John M Schuberth, Jeff C Christensen, and Chad L Seidenstricker
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA., Désirée van der Heijde, Maxime Dougados, Robert Landewé, Joachim Sieper, Walter P Maksymowych, Martin Rudwaleit, Filip Van den Bosch, Jürgen Braun, Philip Mease, Alan J Kivitz, Jessica Walsh, Owen Davies, Lars Bauer, Bengt Hoepken, Luke Peterson, and Atul Deodhar
